title: Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.
abstract: Flow cytometry has become an indispensible tool for the diagnosis and classification of hematopoietic neoplasms. The ability to rapidly distinguish cellular subpopulations via multiparametric assessment of quantitative differences in antigen expression on single cells and enumerate the relative sizes of the resulting subpopulations is a key feature of the technology. More recently, these capabilities have been expanded to include the identification and enumeration of rare subpopulations within complex cellular mixtures, for example, blood or bone marrow, leading to the application for post-therapeutic monitoring or minimal residual disease detection. This review will briefly present the principles to be considered in the construction and use of flow cytometric assays for minimal residual disease detection including the use of informative antibody combinations, the impact of immunophenotypic instability, enumeration, assay sensitivity, and reproducibility.
authors.affiliation: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.|Seattle Cancer Care Alliance, Seattle, Washington.
authors.forename: Brent L
authors.initials: BL
authors.lastname: Wood
mesh_terms: D000906:Antibodies / Q000737:chemistry; D015703:Antigens, CD / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D005434:Flow Cytometry / Q000592:standards*; D015870:Gene Expression; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D006801:Humans; D016130:Immunophenotyping / Q000592:standards*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D011379:Prognosis; D012074:Remission Induction; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016019:Survival Analysis
chemical_list: D000906:Antibodies; D015703:Antigens, CD; D000970:Antineoplastic Agents
keywords: cytometry; leukemia; minimal; monitoring; residual